Gene Therapy ETX101 Improves Seizures and Neurodevelopment in Dravet Syndrome in Phase I/II
New Phase I/II POLARIS data presented at the ASGCT Presidential Symposium show ETX101 delivering durable seizure reduction and early neurodevelopmental gains in children with SCN1A+ Dravet syndrome, highlighting the promise of targeted gene regulation therapy. The post Gene Therapy ETX101 Improves Seizures and Neurodevelopment in Dravet Syndrome in Phase I/II appeared first on GEN - Genetic Engineering and Biotechnology News.
Original Source
Read the full article at Genengnews →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.